Abiomed, Inc. (ABMD) |
|
381.02 0 (0%)
|
12-21 16:00 |
|
Open: |
380.78 |
Pre. Close: |
381.02 |
|
High:
|
381.28 |
Low:
|
380.545 |
|
Volume:
|
15,702,662 |
Market Cap:
|
17,181(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:42:14 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 445.94 One year: 520.86 |
| Support: |
Support1: 378.24 Support2: 376.04 |
| Resistance: |
Resistance1: 381.79 Resistance2: 445.94 |
| Pivot: |
380.33  |
| Moving Average: |
MA(5): 380.97  MA(20): 379.64
MA(100): 308.19 MA(250): 294.47 |
| MACD: |
MACD(12,26): 6.8 Signal(9): 9.2 |
| Stochastic oscillator: |
%K(14,3): 84.4 %D(3): 84.3 |
| RSI: |
RSI(14): 76.2 |
| 52-week: |
High: 381.98 Low: 219.84 |
| Average Vol(K): |
3-Month: 1,669 (K) 10-Days: 4,353 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ABMD ] has closed below upper band by 33.4%. Bollinger Bands are 91.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
382.17 - 384.05 |
384.05 - 385.58 |
|
Low:
|
375.22 - 377.84 |
377.84 - 379.96 |
|
Close:
|
377.39 - 381.32 |
381.32 - 384.5 |
|
Company Description |
|
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson. |
Headline News |
Wed, 21 Dec 2022
A Look At Abiomed Before The $380/Share Buyout From JNJ (ABMD) - Seeking Alpha
Wed, 21 Dec 2022
Johnson & Johnson Announces Extension of Abiomed Tender Offer ... - Johnson & Johnson
Mon, 19 Dec 2022
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join ... - PR Newswire
Mon, 19 Dec 2022
Abiomed leaving S&P 500, replaced by Steel Dynamics (STLD) - Seeking Alpha
Sat, 05 Nov 2022
Is Johnson & Johnson's Purchase of Abiomed Good for Investors? - The Motley Fool
Tue, 01 Nov 2022
Abiomed Announces Second Quarter Revenue of $266 Million, up ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
45 (M) |
| Shares Float |
44 (M) |
|
% Held by Insiders
|
2 (%) |
|
% Held by Institutions
|
97 (%) |
|
Shares Short
|
754 (K) |
|
Shares Short P.Month
|
2,080 (K) |
Stock Financials |
|
EPS
|
5.82 |
|
EPS Est Next Qtl
|
0.56 |
|
EPS Est This Year
|
2.32 |
|
EPS Est Next Year
|
2.67 |
|
Book Value (p.s.)
|
34.09 |
|
Profit Margin (%)
|
24.8 |
|
Operating Margin (%)
|
22.9 |
|
Return on Assets (ttm)
|
9.5 |
|
Return on Equity (ttm)
|
18.2 |
|
Qtrly Rev. Growth
|
7.1 |
|
Gross Profit (p.s.)
|
18.7 |
|
Sales Per Share
|
23.73 |
|
EBITDA (p.s.)
|
6.08 |
|
Qtrly Earnings Growth
|
87 |
|
Operating Cash Flow
|
251 (M) |
|
Levered Free Cash Flow
|
202 (M) |
Stock Valuations |
|
PE Ratio
|
65.35 |
|
PEG Ratio
|
5.2 |
|
Price to Book value
|
11.17 |
|
Price to Sales
|
16.05 |
|
Price to Cash Flow
|
68.45 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
